Umbralisib

Breastfeeding
  • TRADE NAME: Ukoniq (TG Therapeutics)
  • INDICATIONS:

    Relapsed or refractory marginal zone lymphoma (subsequent to an anti-CD20-based regimen) 

    Relapsed or refractory follicular lymphoma (following previous systemic therapy)

     

     

     


  • CLASS: Kinase inhibitor, Phosphoinositide 3-kinase (PI3K) inhibitor
  • HALF-LIFE: 91 hours

FDA APPROVAL DATE: 02/05/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known


May cause fetal harm when administered to a pregnant woman. Advise use of contraceptives.

Our database has 29 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 12/15/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top